Financière de Tubize SAのSMA 200
Financière de Tubize SAのSMA 200は何ですか。
Financière de Tubize SAのSMA 200は€99 +23.27%です。
SMA 200の定義は何ですか。
SMA 200は、過去200日間の終値の非加重平均として計算された過去200日間の平均株価です。
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
EURONEXTのセクタHealth CareにおけるSMA 200の企業と比べるFinancière de Tubize SA
Financière de Tubize SAは何をしますか。
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Financière de Tubize SAと類似のsma 200
- Michelmersh Brick PlcのSMA 200はGBX99 +0.61%です。
- U.S. Physical TherapyのSMA 200は$99 -18.88%です。
- adesso AGのSMA 200は€99 -70.91%です。
- Jagran PrakashanのSMA 200は₨99 +7.80%です。
- Insperity IncのSMA 200は$99 -14.90%です。
- Marwyn Value InvestorsのSMA 200はGBX99 -5.44%です。
- Financière de Tubize SAのSMA 200は€99 +23.27%です。
- Marwyn Value InvestorsのSMA 200はGBX99 +57.44%です。
- Jagran PrakashanのSMA 200は₨99 +6.99%です。
- Restaurant Brands InternationalのSMA 200はCAD$99 -6.10%です。
- iShares VI Public - iShares Euro Corporate Bond s UCITS ETFのSMA 200は€99 +1.58%です。
- Akamai TechnologiesのSMA 200は$99 -3.75%です。
- Akamai Technologies IncのSMA 200は$99 -2.74%です。